 Patent Application Title |
Patent App Num. |
Date |
 Estimating apparatus and estimating method | 20130123642 | 20130516 |
 A photodynamic therapy apparatus as an estimating apparatus is an apparatus for irradiating a tissue having absorbed photo-sensitive pharmaceutical, the photo-sensitive pharmaceutical absorbing an excitation light and emitting fluorescence, with the excitation light emitted from a tip portion of a laser the catheter, including a connector, a light source, and a light detection unit. The laser the catheter is capable of being attached/detached to/from the connector. The light source outputs the excitation light to the laser the catheter via the connector. The light detection unit detects intensity or a spectrum of the fluorescence, the fluorescence being entered from the laser the catheter via the connector, to estimate whether the tissue has changed because of reaction between the excitation light emitted from the tip portion of the... |
| Illuminator for photodynamic therapy | 20130102906 | 20130425 |
 An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic ballasts. The spacing of the U-shaped tubes is varied to increase the output at the edges of the illuminator to make the output more uniform. Also, different portions of the tubes are cooled at different amounts, to improve uniformity. A light sensor monitors output from the U-shaped tubes to provide a signal for adjusting the output from the tubes.
... |
| Use of aminolevulinic acid and derivatives thereof | 20130090592 | 20130411 |
 The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said... |
| Apparatus and method for performing photodynamic diagnosis and photodynamic therapy | 20130053699 | 20130228 |
 An apparatus for performing photodynamic diagnosis and photodynamic therapy on a target region that is pre-given with a photosensitizer precursor includes a display unit, an excitation light source operable to irradiate the target region with exciting light so as to excite emission of fluorescence from the target region as a result of fluorescence response of the photosensitizer precursor, an image capturing unit operable to capture a white light image and a fluorescent image of the target region, an image processing unit operable to superimpose the white light image and the fluorescent image into a synthesized image and to provide at least one of the white light image, the fluorescent image and the synthesized image thereto for display on the display unit, and a curing light source... |
| Devices and methods for conforming photodynamic therapy to specific anatomic locations | 20130029286 | 20130131 |
 A device for conforming photodynamic therapy to a specific anatomic location (e.g., in the oral cavity) conforms the radiation to the target tissue surface and avoids delivering light to the rest of the oral cavity. Embodiments can include a body of oral impression material molded to conform to the anatomic surface, a light pipe, a freeform reflector formed on a surface of the optical body, or a light guide having a textured surface to direct light to an opposing output window. The light guide can be made of flexible plastic to conform the output window to the lesion.
... |
| |
| Microwave induced photodynamic therapy | 20130012754 | 20130110 |
| A method of administering photodynamic therapy includes using a microwave frequency-sensitive light-emitting polymer as a light source to excite a administered photosensitizer to exert cytotoxicity in situ at a site containing undesired or diseased tissue.
... |
| Carbonylporphyrins and uses thereof | 20130004419 | 20130103 |
| The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT), and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing porphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
... |
| Irradiation device | 20120330219 | 20121227 |
| An irradiation device for insertion into an orifice of the body for providing photodynamic therapy or diagnosis comprises: a housing 1, 21, 31, 51, 61, 71 adapted to be fully inserted and secured in the orifice, the housing 1, 21, 31, 51, 61, 71 enclosing an LED lamp system 5, 25, 35, 45, 54, 62, 72 and a power source 41, 68, 78, for powering the LED lamp system 5, 25, 35, 45, 54, 62, 72, wherein the device is independently operational while within the orifice.
... |
| Nonlinear optical photodynamic therapy (nlo-pdt) of the cornea | 20120330291 | 20121227 |
| The embodiments include method of nonlinear optical photodynamic therapy of tissue including the steps of providing pulsed infrared laser light for two-photon excited fluorescence tissue exposure, and selectively focusing the pulsed infrared laser light within the tissue at a focal plane to activate a photosensitizing agent to generate free radicals within a highly resolved axial and lateral spatial domain in the tissue. The invention is also directed to an apparatus for performing nonlinear optical photodynamic therapy of tissue including a pulsed infrared laser for providing two-photon excited fluorescence beam tissue exposure, a scanner for selectively and controllably moving the tissue and the beam relative to each other, and optics for selectively focusing the pulsed infrared laser light within the tissue at a point in a focal... |
| Catheter for performing photodynamic ablation of cardiac muscle tissue via photochemical reaction | 20120330293 | 20121227 |
| This invention provides a catheter used for blocking abnormal conduction in the cardiac muscle using photodynamic therapy or treating arrhythmia and a method for evaluating the therapeutic effects of the catheter. The catheter has a structure that freely bends at its end, which is used for performing photodynamic ablation of cardiac muscle tissue via photochemical reactions in the blood vessel or cardiac lumen. The catheter comprises a light-emitting window for applying a light beam transmitted through an optical fiber to a target site of cardiac muscle tissue and at least two electrodes for potential measurement in the periphery of the light-emitting window.
... |
| Methods and compositions for treating conditions of the eye | 20120323162 | 20121220 |
| Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.
... |
| Photodynamic therapy with phthalocyanines and radical sources | 20120323164 | 20121220 |
| The use of phthalocyanines together with a free radical source for photodynamic therapy is described. The free radical sources cause the photodecomposition of the phthalocyanines, which can be useful for various reasons such as allowing light to penetrate to lower tissue levels that would otherwise be obscured. The nature of the phthalocyanine and the free radical source chosen can both have an influence on the rate of photodecomposition. The free radical sources can be provided along with the phthalocyanines either in free unattached form, or they can be attached to the phthalocyanines themselves.
... |
| Drug delivery system and method of treatment of vascular diseases using photodynamic therapy | 20120310142 | 20121206 |
| This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.
... |
| |
| Vision through photodynamic therapy of the eye | 20120310144 | 20121206 |
| Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects.
... |
| Materials and accessories for the application of antibacterial photodynamic therapy | 20120310310 | 20121206 |
| An apparatus for carrying out antibacterial photodynamic therapy that includes an illumination means and a means for dispensing the photosensitizer, wherein the means for dispensing the photosensitizer is adapted in such a manner that the photosensitizer is dispensed in spatial proximity to the body region to be treated.
... |
| Biologically active methylene blue derivatives | 20120302557 | 20121129 |
| exposing the area to light to activate the compound.
... |
| Continuous low irradiance photodynamic therapy illumination system | 20120303101 | 20121129 |
| A system for photodynamic therapy is provided that includes a light delivery device that delivers the illumination necessary to perform photodynamic therapy. The light delivery device includes one or more etched fibers arranged to illuminate a selective region of a body for photodynamic therapy. An illumination device is coupled to the light delivery device to provide the necessary illumination to the light delivery device.
... |
| Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses | 20120294801 | 20121122 |
| Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.
... |
| Device and method for photodynamic therapy | 20120296260 | 20121122 |
| The invention relates to an apparatus for photodynamic therapy and/or for destroying or reducing microorganisms, comprising an irradiation unit having at least one light source, by means of which a photosensitizer applied to a wound area to be treated is activated by way of irradiation, further comprising a camera for recording images of the wound, which is disposed in the irradiation unit, and a positioning unit, by means of which the irradiation unit can be oriented with respect to the wound area. The invention further relates to a method for operating such an apparatus. On a display for the images is a grid with visual indicia distinguishing fields to be irradiated by means of the light sources.
... |
| Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris | 20120296263 | 20121122 |
| Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various intervals. At low doses of ALA and photodynamic therapy (PDT) in single or multiple treatments, improvement in the sebaceous gland disorder, e.g., acne, provides the discovery that diminishment in sebum secretion and the eradication of bacteria occurs. At high doses of ALA and a single high energy PDT treatment, permanent changes to the sebaceous gland and sebum secretion have been discovered.
... |
| Photosensitizers for targeted photodynamic therapy | 20120264802 | 20121018 |
| The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.
... |
| Synthesis of 2-(4-aminophenyl) benzothiazole derivatives and use thereof | 20120215154 | 20120823 |
| The present invention also provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R1 and R2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue; wherein growth of the tumor is inhibited.
... |
| Singlet oxygen production and dosimetry for photodynamic therapy | 20120209125 | 20120816 |
| An apparatus for photodynamic therapy (PDT) includes a light source configured to provide excitation light for a photosensitizer, an optical system configured to direct the excitation light to a target region and receive light emitted by the photosensitizer and/or singlet oxygen generated in the target region, and a detection system configured to receive the light emitted by the photosensitizer and/or the singlet oxygen. The apparatus also includes a filter system configured to spectrally discriminate between emission from the photosensitizer and the singlet oxygen and a processor configured to determine concentrations of the singlet oxygen and/or the photosensitizer based on an emission signal measured by the detection system.
... |
| Targeted nano-photomedicines for photodynamic therapy of cancer | 20120184495 | 20120719 |
| The present invention relates to a photosensitizer-containing nanoparticle, comprising a photosensitizer covalently bonded throughout at least a part of said nanoparticle to the nanoparticle matrix material and incorporated therein in a quasi-aggregated state. The present invention further relates to methods for producing the invention nanoparticles, and to methods of killing cancer cells by PDT treatment using the said nanoparticles.
... |
| Photodynamic therapeutic agent having cell-specific active accumulation properties | 20120164210 | 20120628 |
| The present invention relates to a cancer-cell-specific polymer compound containing a photosensitizer for photodynamic therapy and having a surface to which an antibody against a cancer-cell-specific antigen binds. An object of the present invention is to provide a photodynamic therapeutic agent that can reach the cancer tissue at a low concentration via active targeting and makes complications (e.g., sunlight hypersensitivity) associated with photodynamic therapy unlikely to occur.
... |
| Novel method for microbes depletion in human blood or full serum using antimicrobial photodynamic laser therapy | 20120094269 | 20120419 |
| Treatment methods/devices are provided for attenuating/inactivating the pathogenic microbes found in biological fluids e.g. blood/blood products including human single-donor-fresh-frozen-plasma, platelet concentrate, red blood cells, blood clotting factors. An Antimicrobial Photodynamic Therapy method is used to eliminate multiple (resistant) bacteria, viral agents, fungi, parasites and other undetected or non-easily detected pathogenic microbes or particles in blood and blood products without affecting their biological properties. Resistant bacteria are difficult to be eliminated. This is especially true in the case for S. aureus and related strains, Staphylococcus epidermidis or Propionibacterium acnes, Borrelia species and other bacteria found on skin. Further embodiments eliminate undetected or non-easily detected viral agents contaminating blood/blood products responsible for spreading hepatitis, Acquired ImmunoDeficiency Syndrome and other blood borne viral diseases. Human Immunodeficiency, hepatitis B and... |
| Photodynamic therapy including light pretreatment | 20120071810 | 20120322 |
| A method of photodynamic therapy is described that includes administering a therapeutically effective amount of a photosensitizer to an area of tissue such as the skin of a subject, delivering a first photoirradiation with light having a wavelength suitable to activate the photosensitizer to the area of skin, allowing a sufficient interval of time to pass for an effective amount of the photosensitizer to penetrate the tissue, and then delivering a second photoirradiation with light having a wavelength suitable to activate the photosensitizer to provide a therapeutic effect. Use of multiple photoirradiations increases the speed with which the photosensitizer can penetrate the tissue to reach the area where the source of the disease is present.
... |
| Novel chlorin e6-folic acid conjugate, preparation method thereof, and a pharmaceutical composition for the treatment of cancer comprising the same | 20120059018 | 20120308 |
| The present invention relates to a novel chlorin e6-folic acid conjugate, a preparation method thereof, and a pharmaceutical composition for the treatment of cancer comprising the same, and more particularly, to a novel compound prepared by linking chlorin e6 to folic acid, which effectively produces singlet oxygen in various media and has much better tumor selectivity than the known porphyrin-based photosensitizers, thereby being used effectively in photodynamic therapy for malignant tumors, a preparation method thereof, and a pharmaceutical composition for photodynamic treatment of solid tumors comprising the compound.
... |
| Composition for photodynamic therapy comprising a macromolecular capsule | 20120045516 | 20120223 |
| A composition for photodynamic therapy including a polymer capsule having a diameter of about 10 nm to about 2000 nm synthesized by copolymerization of a flat aromatic compound represented by Formula 1 (see the specification) and an organic compound represented by Formula 2 (see the specification).
... |
| Photodynamic therapy for conditions of the eye | 20120041356 | 20120216 |
| The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.
... |
| Feedback-controlled method for delivering photodynamic therapy and related instrumentation | 20100331927 | 20101230 |
| A method for delivering photodynamic therapy (PDT) while performing dose metric monitoring and treatment feedback-driven control is presented. Photodynamic therapy is initiated with irradiation of light at a first irradiance. A set of fluorescence and reflectance spectroscopic measurements are taken at prescribed intervals during the therapy of the treatment region. Spectra are analyzed to determine dose metrics of the therapy such as fluorescence photobleaching of the sensitizer and blood oxygen status and optical properties of the treatment region. This information is then used to determine an optimal fluence rate given those parameters and the region is irradiated with a second irradiance. This process is continued until either the entire prescribed fluence is delivered to the region or a predetermined extent of photosensitizer bleaching is achieved.
... |
| Drug delivery system and method of treatment of vascular diseases using photodynamic therapy | 20100331819 | 20101230 |
| This invention relates to photodynamic therapy (PDT), more specifically PDT for atherosclerotic plaque via delivering PDT-loaded nanoparticles such as liposomes, polymersomes, micelles and polymeric nanoparticles into the diseased vascular tissue. This invention provides method and formulations for delivering multiple drugs and delivering drugs to specific targeted site.
... |
| Method for selective photodynamic therapy and light source for implementation thereof | 20100312312 | 20101209 |
| Disclosed is a method of photodynamic therapy that includes introducing a selective photocytotoxic compound to a body having a target cell, wherein the selective photocytotoxic compound is configured to selectively attach to or enter the target cell. The method further includes activating the selective photocytotoxic compound with a light source. Further disclosed is a method that includes introducing a selective photoluminescent compound to a body having a target material. The selective photoluminescent compound is configured to selectively attach to or enter the target material. The method includes introducing an activating light to the selective photoluminescent compound, wherein the photoluminescent compound is configured to absorb the activating light and emit an emission light having a different wavelength than the activating light for diagnosis and locating diseased areas.... |
| Cosmetic rejuvenation by photodynamic therapy | 20100312167 | 20101209 |
| A PhotoDynamic Therapy (PDT) method is presented for cosmetic rejuvenation, which is exemplified by a two phase approach for treating facial and neck skin aging while minimizing damage to the underlying region of skin being treated. To obtain best results a combination of treatments are used. This includes applying photosensitizer and light energy for stimulating the collagen within the skin, thereby restoring the elasticity of skin. The treatment procedures take about six weeks consisting of impair(damage) and repair (recovery) sessions involving skin preparation by peeling, skin detoxification, application and distribution of photosensitizer to the skin, irradiation of pre-sensitized skin followed by removal of mask. Results of long lasting improvement, especially in comparison with most cosmetic treatments, are obtained upon completion of the series, with marked changes... |
| Induction device for photodynamic therapy and diagnosis | 20100305666 | 20101202 |
| An induction device for photodynamic therapy and diagnosis is used in a living body, and for activating a photochemical reaction of a photosensitive agent in the living body. The induction device comprises a transmitter, and a light irradiator implanted in the living body. The transmitter is used for emitting a radio signal to penetrate a superficial layer of the living body. When the light irradiator receives the radio signal, the light irradiator emits light by the driving signal, such that the photosensitive agent undergoes a photochemical reaction.
... |
| Method for photodynamic therapy and apparatus therefor | 20100305494 | 20101202 |
| Photodynamic therapy is used in the treatment of orthopaedic infections. Particularly, it is used in the treatment of infections related to orthopaedic conditions and surgery and includes treatment of sites of deterioration or trauma, such as prior to and after prosthetic fixation such as joint replacement or treatment of trauma sites such as pinning of bone fractures. An orthopaedic disinfection apparatus includes a photosensitiser and a light delivery system capable of producing and delivering light at a wavelength which is capable of being absorbed by the photosensitiser. Methods of treatment of orthopaedic infections are also disclosed.
... |
| Metallocorroles | 20100305335 | 20101202 |
| Metallocorrole complexes of third row transition metals may be used as therapeutic agents, catalysts, components of oxygen detectors, and components of light emitting diodes. In particular, metallocorrole complexes of third row transition metals may be used as improved photosenitizers in photodynamic therapy; as improved catalysts in aziridination, epoxidation, and water splitting reactions; as improved in vivo imaging agents; and as improved components in the emissive layer of OLEDs. Due to their strongly sigma-donating nature, corroles are able to stabilize third row transition metals in high oxidation states. Third row transition metals are significantly more electropositive than their first and second row counterparts and may therefore act as improved catalysts. In addition, the high spin-orbit coupling constants of third row transition metals may lead to easier singlet-triplet... |
| Use of an agent that restores tissue perfusion and oxygenation | 20100298222 | 20101125 |
| The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations... |
| Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate | 20100297762 | 20101125 |
| A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.
... |
| Method for controlling photodynamic therapy irradiation and related instrumentation | 20100292762 | 20101118 |
| In a first embodiment, there is no monitoring, and instead light is delivered according to a predetermined ‘recipe.’ In a second embodiment, the instrumentation provides a means for making the reflectance measurements during therapy without requiring the brief interruption. This device may therefore allow more accurate measurement of treatment-induced changes to the reflectance measurement. In a third embodiment, an adjustable aperture is used to constrict the area of a treatment beam.
... |
| Device for treatment of blood vessels using light | 20100274330 | 20101028 |
| Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve... |
| Oral formulations for tetrapyrrole derivatives | 20100273803 | 20101028 |
| Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles. The oral formulation, in case of a hydrophobic photosensitizer in the present invention, is stabilized using suitable surfactants/solubilizers thus preventing aggregation of... |
| Novel compounds useful in therapeutic and cosmetic methods | 20100273725 | 20101028 |
| The present invention relates to photosensitizer compounds for use in cosmetic and therapeutic applications of photodynamic therapy. The compounds of the present invention are designed for topical application and are characterized by a low permeability to the stratum corneum (the outer skin layer of an individual) and/or a low allergenic potential. Surprisingly, such compounds have beneficial properties in the treatment of certain diseases and lack the undesired damages to healthy skin entailed by prior art compounds. ALA (5-aminolevulinic acid)-esters of body-owned, natural compound such as aminoacids, steroids, carbohydrades, alcohols are preferred, examples of photosensitizers of the present invention. The compounds of the present invention are used in the treatment of skin diseases such as psoriasis, sebaceous glands related conditions including acne, seborrhoic dermatitis, rosacea, skin cancer... |
| Nanoparticles for cancer sonodynamic and photodynamic therapy | 20100262115 | 20101014 |
| The present invention is directed to nanoparticles comprising a cancer therapeutic, pharmaceutical compositions comprising same, and methods for using same for drug delivery and ultrasound or light-based treatment of cancer.
... |
| Use of improved toluidine blue in photodynamic therapy | 20100256125 | 20101007 |
| A method of treating oral cancer is provided. The method comprises the steps of providing at least one photodynamic treatment comprising the steps of (i) applying a composition comprising improved toluidine blue to oral cells; wherein the composition comprises a greater percentage by weight of the conformational isomers of toluidine blue compared to the N-demethylated derivatives thereof; and wherein the composition localizes to oral cancer cells; and activating the applied composition, thereby killing the oral cancer cells.
... |
| Liposomal ala pharmaceutical and cosmeceutical compositions and methods of treatment | 20100255080 | 20101007 |
| Liposomal ALA pharmaceutical and cosmeceutical compositions, and methods of treatment are disclosed herein. In an embodiment, a Liposomal ALA composition of the present disclosure is used in for photodynamic therapy. In an embodiment, a photodynamic therapy system is disclosed that includes nanocorpuscles comprising 5-aminolevulinic acid in a scattering agent, wherein a concentration of the 5-aminolevulinic acid is from about 0.01% to about 10%; and a light source for activating the 5-aminolevulinic acid. In an embodiment, a photodynamic therapy method is disclosed that includes administering nanocorpuscles comprising 5-aminolevulinic acid to a target tissue in a patient; and activating the 5-aminolevulinic acid with a light source. In an embodiment, a kit is disclosed.
... |
| Composition for photodynamic skin treatment | 20100255045 | 20101007 |
| The invention relates to a composition for photodynamic therapy. The composition of the invention, in the form of a gel or a cross-linked hydrogel, includes a chlorophyll photosensitising substance or a derivative thereof, in particular chlorophyllin optionally associated with an additional ingredient such as an alpha- or beta-hydroxy acid, a depigmentation or lightening agent, and/or an antioxidant. The invention can be used in the treatment of skin aging signs and in skin regeneration.
... |
| Pegylated compounds for age-related macular degeneration | 20100247626 | 20100930 |
| A special photosensitizer formulation and Photodynamic Therapy method for treating choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) is provided. CNV is a major cause for vision loss in elderly patients. A special drug delivery formulation is used to encapsulate the hydrophobic photosensitizer, preferably a pegylated liposome. This improves the solubility and therapeutic index of the photosensitizers. In one preferred embodiment, a pegylated photoactive agent remains confined in the intravascular compartment of neovasculature for a longer duration. Thus efficient elimination of neovascular proliferation and minimal damage to extravascular tissue and normal vessels is ensured. In this method, a hydrophobic photosensitizer, that is able to photochemically destroy neovessels, is injected into the patient. CNV irradiation with a non-thermal laser follows after a predefined time interval. The... |
| In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles | 20100247436 | 20100930 |
| Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
... |
| Phthalocyanine salt formulations | 20100240609 | 20100923 |
| Pharmaceutical compositions of phthalocyanine compounds with a structure according to Formula (I) are described. Phthalocyanines are photosensitizer compounds having a phthalocyanine ring system that can be used for photodynamic therapy. Different phthalocyanines and phthalocyanine salts are shown to have useful characteristics such as water solubility, oil solubility, or tunable photostability. Formulations of phthalocyanines and phthalocyanine salts that can be used for topical and systemic administration are described.
... |
| Simultaneous photodynamic therapy and photo induced polymerization | 20100227799 | 20100909 |
| Described herein are methods and compositions for the combined treatments of photodynamic therapy and photo-induced polymerization. The wavelength of light needed to accomplish both therapies can be different or can be the same. In one embodiment, the photodynamic therapy is performed first and the photo-induced polymerization is performed thereafter. In other embodiments, both treatments are performed simultaneously.
... |
| Novel photosensitizer based on polymer derivatives-photosensitizer conjugates for photodynamic therapy | 20100222538 | 20100902 |
| Disclosed is a novel photosensitizer based on polymer derivatives-photosensitizer conjugates for photodynamic therapy capable of being selectively accumulated in cancerous tissues and producing singlet oxygen or free radical by laser irradiation. The polymer derivatives-photosensitizer conjugates for photodynamic therapy are prepared as nano-sized particles, and have excellent selection and accumulation ratio for cancerous tissues. The photosensitizer conjugates can produce singlet oxygen or free radical by a specific laser wavelength. Owing to the excellent selection and accumulation ratio for cancerous tissues, the conjugates minimizes photo-cytotoxicity of the conventional photosensitizer having a low molecular amount. Accordingly, the conjugates are very useful as a photosensitizes for photodynamic therapy with reduced side effects and excellent therapeutic effectiveness.
... |
| Acne therapeutic agent and sebum secernent inhibitor which comprise indole-3-alkylcarbo xylicacid, and kits for photodynamic therapy containing the same | 20100211137 | 20100819 |
| The present invention relates to novel uses of indole-3-alkylcarboxylic acid and derivatives thereof as a photosensitizer for the treatment of acne or for the inhibition of sebum secretion. More particularly, the present invention is directed to a photosensitizer for photodynamic therapy, a photodynamic therapy kit and photodynamic therapeutic composition comprising thereof, which contain indole-3-alkylcarboxylic acid being activated by light. The light which activates indole-3-alkylcarboxylic acid of the present invention may be ultraviolet rays or visible lights, preferably blue light or green light.
... |
| Tumour growth inhibitory compounds and methods of their use | 20100196356 | 20100805 |
| Specific CpG oligonucleotide sequences, when given subcutaneously and in particular when administered on a mucous membrane, e.g. intranasally, intravaginally, or rectally, have a profound effect on various human cancer forms as confirmed in vivo, in animal studies, and in vitro, in human PBMCs collected from blood from healthy subjects and from patients suffering from CLL or FL. The compounds are also preferably used in combination with a cancer therapy chosen among radiation treatment, hormone treatment, surgical intervention, chemotherapy, immunological therapies, photodynamic therapy, laser therapy, hyperthermia, cryotherapy, angiogenesis inhibition, or a combination of any of these, and is most preferably an immunological treatment and comprises the administration of an antibody to the patient.
... |
| Illuminator for photodynamic therapy | 20100191172 | 20100729 |
| An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic ballasts. Adjustment of the ballast voltage controls the output power of the tubes. The tubes are supported by a sheet-metal or plastic housing and are covered by a polycarbonate shield which directs cooling airflow within the unit and prevents glass-patient contact in the vent of tube breakage. An aluminum reflector located behind the tubes increases both the output irradiance and the uniformity of the output distribution. The spacing of the U-shaped tubes is varied to increase... |
| Porphyrin-based compounds for tumor imaging and photodynamic therapy | 20100184970 | 20100722 |
| This invention describes a first report on the synthesis of certain 124I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy (PDT). The development of tumor imaging or improved photodynamic therapy agent(s) itself represent an important step, but a dual function agent (PET imaging and PDT) provides the potential for diagnostic body scan followed by targeted therapy.
... |
| Photosensitizers for targeted photodynamic therapy | 20100184818 | 20100722 |
| The present invention provides photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.
... |
| Method and apparatus for optical inhibition of photodynamic therapy | 20100174223 | 20100708 |
| A system and method are provided for preventing damage to the epidermis or other epithelial or non-target tissue during photodynamic therapy treatment. For example, an inhibiting radiation can be used to control formation of a photosensitizer from a precursor photosensitizer in the epidermis or epithelial tissue. Subsequent application of a treatment radiation can activate the photosensitizer to damage or destroy target sites while the non-target tissue remains substantially unaffected.
... |
| Organometeallic compounds | 20100173885 | 20100708 |
| The present invention relates to novel organometallic compounds for use as a medicine, in particular in photodynamic therapy against various diseases, such as cancer or inflammatory and/or immune disorders. The compounds comprise a central porphyrin or phtalocyanine backbone to which ligand linkers coordinated to at least one transition metal are attached. Eta-5 or eta-6 arenes further bind to the transition metal. According to a preferred embodiment, the compound is a tetranuclear Ruthenium (+II) complex.
... |
| Device and method for irradiating tissue with light pulses | 20100168824 | 20100701 |
| The invention relates to a device (1) for irradiating tissue (G) with light pulses (L), comprising a housing (2), at least one light source (3) for emitting the light pulses (L) with a wavelength (λ) of from 600 nm to 660 run, a modulator (4) and a power stage (6) for generating the light pulses (L), and with an activating element (5). For creating a device (1) which is as small, as cost-efficient and as effective as possible, by which as good a therapy success as possible is achieved in various applications, the modulator (4) is designed for generating the light pulses (L) with a pulse frequency (f) of from 1 to 10 Hz, and the power stage (6) is designed for emitting the light pulses... |
| Anti-microbial photodynamic therapy | 20090326434 | 20091231 |
| Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The key to these conjugates is a special spacer connecting at least one photosensitizer to a microorganism receptor (vector) which in turn binds selectively to the surface of a microorganism bringing about photo-destruction upon irradiation. Spacers having hydrophilic structure such as ethylene glycol units and amino carboxyl end capped ethylene glycol units must be used for linking the vector to the photosensitizer. In a preferred embodiment a spacer would have at least 3 ethylene glycol units and be end capped with a carboxyl group on one end and a amino group at the other end. The present invention effectively works to combat bacterial infection in... |
| Light diffuser and process for producing the same | 20090318912 | 20091224 |
| A light diffuser (10), which is particularly suitable for introducing diffuse light into a tissue, is produced by interpenetration of a diffuser material in a liquid state into a boundary layer (4) of a porous shaping material, by which process a diffuser surface is formed having a surface structure which represents essentially a negative of the pore structure of the shaping material and includes undercut structures induced by a surface tension. The light diffuser (10) is e.g. produced by introducing a diffuser blank (1) including material which is liquefiable through mechanical vibration into the shaping material and simultaneously stimulating it with mechanical vibrations, such that the liquefiable material liquefies at least there where it is in contact with the shaping material and is pressed into the... |
| Boron-containing porphyrin compounds and their uses | 20090318680 | 20091224 |
| Boron-containing porphyrin compounds are disclosed that may be used for boron neutron capture therapy of tumors, radiotherapy of tumors, and photodynamic therapy of tumors.
... |
| Novel glycoconjugated chlorin derivatives and method of producing the same | 20090318370 | 20091224 |
| Disclosed is a novel glycoconjugated chlorin derivative which is useful as a substance for photodynamic therapy, is stable, and can act a photosensitizer having high phototoxicity even when used in a small quantity. Also disclosed is a method of producing the derivative. Specifically disclosed are a S-glycosylated chlorin derivative represented by the following general formula (1) and a metal complex thereof. In the general formula (1), X1 to X20 independently represent a group selected from the group consisting of F—, sugar-S—, sugar-Z-S— and sugar-O-Z-S— and at least one among X1 to X20 represents a group selected from the group consisting of sugar-S—, sugar-Z-S— and sugar-O-Z-S— (wherein F represents a fluorine atom, Z represents an oxygen atom, Z represents a hydrocarbon group having 1 to 6 carbon... |
| Compositions and methods relating to target-specific photodynamic therapy | 20090304803 | 20091210 |
| The invention generally provides methods and compositions useful for providing photodynamic therapy to specific cells or tissues.
... |
| Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris | 20090299268 | 20091203 |
| Light treatments of sebaceous gland disorders with 5-aminolevulinic acid and photodynamic therapy are disclosed. A preferred treatment includes topical application of 5-aminolevulinic acid to the skin followed by light exposures with repeated treatment at various intervals. At low doses of ALA and photodynamic therapy (PDT) in single or multiple treatments, improvement in the sebaceous gland disorder, e.g., acne, provides the discovery that diminishment in sebum secretion and the eradication of bacteria occurs. At high doses of ALA and a single high energy PDT treatment, permanent changes to the sebaceous gland and sebum secretion have been discovered.
... |
| Methods and compositions for treating conditions of the eye | 20090286743 | 20091119 |
| Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.
... |
| Use of fusarochromanone and its derivatives in the diagnosis and treatment of cancer and other diseases | 20090258941 | 20091015 |
| A method of photodynamic therapy to treat diseased cells in an animal is generally provided. According to the method, 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is administered to the animal such that the 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof accumulates in the diseased cells. Then, the diseased cells containing 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is exposed to light energy (e.g., ultraviolet light).
... |
| Methods and compositions for dose-dependent photodynamic therapy of disorders | 20090259167 | 20091015 |
| The invention provides methods and compositions for treating a tissue disorder in a subject by parenterally administering a solution of aminolevulinic acid (ALA) or a derivative thereof that is not greater than 1.0 percent by weight into a local subcutaneous or dermal region of the subject; and administering high fluence light to said bodily area to produce a phototoxic species in said local region, thereby treating a tissue disorder in the subject.
... |
| Combined oct catheter device and method for combined optical coherence tomography (oct) diagnosis and photodynamic therapy (pdt) | 20090240154 | 20090924 |
| In a catheter device and a method for in vivo activation of a photosensitizing drug in a vessel, endovascular tissue, and/or intraluminal tissue, a catheter carrying both an optical coherence tomography (OCT) lens, from which OCT imaging light is emitted, and a photodynamic therapy (PDT) lens from which photosensitizing drug-activating light is emitted, is inserted into a vessel containing a lesion to be treated. A photosensitizing drug is caused to be placed in the vessel as well, such as in the form of a coating on a stent or a coating on an exterior of a balloon carried by the catheter. Light is emitted from the PDT lens to activate the photosensitizing drug while light is simultaneously emitted from the OCT lens to obtain an OCT... |
| De novo synthesis of bacteriochlorins | 20090226467 | 20090910 |
| to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.
... |
| Synthesis of chlorins and phorbines with enhanced red spectral features | 20090227553 | 20090910 |
| The present invention provides compounds of the general Formula DI: along with methods of making such compounds, formulations containing the same, and methods of using the same (e.g., in photodynamic therapy, for the production of solar cells, etc.)
... |
| Tetraazaporphyrin-based compounds and their uses | 20090215105 | 20090827 |
| Asymmetrically substituted metal-phthalocyanine compounds are disclosed. These compounds and other phthalo-cyanine-derivatives are used in bioimaging, bioanalysis, FRET and quenching techniques, photodynamic therapy, DNA analysis for cells, proteins, tissues and other biological entities, and other applications. Near-infrared fluorescence minimizes matrix effects typically seen in other methods of analyzing biochemical entities in cells, proteins, tissues and other biological entities.
... |
| Tetraazaporphyrin-based compounds and their uses | 20090215105 | 20090827 |
| Asymmetrically substituted metal-phthalocyanine compounds are disclosed. These compounds and other phthalo-cyanine-derivatives are used in bioimaging, bioanalysis, FRET and quenching techniques, photodynamic therapy, DNA analysis for cells, proteins, tissues and other biological entities, and other applications. Near-infrared fluorescence minimizes matrix effects typically seen in other methods of analyzing biochemical entities in cells, proteins, tissues and other biological entities.
... |
| Tetraazaporphyrin-based compounds and their uses | 20090215105 | 20090827 |
| Asymmetrically substituted metal-phthalocyanine compounds are disclosed. These compounds and other phthalo-cyanine-derivatives are used in bioimaging, bioanalysis, FRET and quenching techniques, photodynamic therapy, DNA analysis for cells, proteins, tissues and other biological entities, and other applications. Near-infrared fluorescence minimizes matrix effects typically seen in other methods of analyzing biochemical entities in cells, proteins, tissues and other biological entities.
... |
| Tetraazaporphyrin-based compounds and their uses | 20090215105 | 20090827 |
| Asymmetrically substituted metal-phthalocyanine compounds are disclosed. These compounds and other phthalo-cyanine-derivatives are used in bioimaging, bioanalysis, FRET and quenching techniques, photodynamic therapy, DNA analysis for cells, proteins, tissues and other biological entities, and other applications. Near-infrared fluorescence minimizes matrix effects typically seen in other methods of analyzing biochemical entities in cells, proteins, tissues and other biological entities.
... |
| Tetraazaporphyrin-based compounds and their uses | 20090215105 | 20090827 |
| Asymmetrically substituted metal-phthalocyanine compounds are disclosed. These compounds and other phthalo-cyanine-derivatives are used in bioimaging, bioanalysis, FRET and quenching techniques, photodynamic therapy, DNA analysis for cells, proteins, tissues and other biological entities, and other applications. Near-infrared fluorescence minimizes matrix effects typically seen in other methods of analyzing biochemical entities in cells, proteins, tissues and other biological entities.
... |
| Medical light diffusers for high power applications and their manufacture | 20090210038 | 20090820 |
| A high power density light delivery device is presented that uses an optical fiber with a diffuser attached at a distal end for use in, for example, photodynamic therapy (PDT) and laser induced thermotherapy (LITT). Uniform scattering in the diffuser section is obtained by either inducing differences in refractive index profiles of the core or in the core-cladding interface with the use of scattering centers or nano-voids. Nano-voids are created in the core or core-cladding interface by focusing high power laser energy or picosecond/femtosecond laser pulses on the quartz fiber material to induce defects. A special method is used that writes defects into or near to the core/cladding boundary through the jacket, without the necessity to first remove the jacket and then recoat the fiber. The... |
| Medical light diffusers for high power applications and their manufacture | 20090210038 | 20090820 |
| A high power density light delivery device is presented that uses an optical fiber with a diffuser attached at a distal end for use in, for example, photodynamic therapy (PDT) and laser induced thermotherapy (LITT). Uniform scattering in the diffuser section is obtained by either inducing differences in refractive index profiles of the core or in the core-cladding interface with the use of scattering centers or nano-voids. Nano-voids are created in the core or core-cladding interface by focusing high power laser energy or picosecond/femtosecond laser pulses on the quartz fiber material to induce defects. A special method is used that writes defects into or near to the core/cladding boundary through the jacket, without the necessity to first remove the jacket and then recoat the fiber. The... |
| Trans-splicing mediated photodynamic therapy | 20090203143 | 20090813 |
| The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity.
... |
| Prevention and treatment of cancer and other diseases | 20090203636 | 20090813 |
| Nucleoside chemical compounds, which interact with specific structures of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) are disclosed. The compounds interfere with the activities of telomerase and reverse transcriptase, and are useful as antivirals, antibacterials and anticancer agents. Methods of treating or preventing cancers in patients involving administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptases (RTs) expressed in cells of the patients are also disclosed. Method of using nucleoside analogs and other inhibitors of RTs in conjunction with DNA damaging agents such as genotoxic agents or radiation or photodynamic therapy or combinations these for the treatment of various cancers are also disclosed.
... |
| Ethylene glycol esters as photoactive agents | 20090203757 | 20090813 |
| R2 is vinyl or a derivative form thereof.
... |
| Method and device for photodynamic therapy | 20090204057 | 20090813 |
| The present invention relates to a photodynamic therapy method and uses thereof for treating an individual in need thereof, comprising administering a photosensitizer to an individual and activating the photosensitizer with a chemiluminescent light source, and/or a light-emitting diode light source, wherein the light source is in dermal contact with the individual. The present invention also relates to a device for photodynamic therapy comprising a permeable reservoir, for containing a photosensitizer formulation for skin application, the device is adapted to deliver the photosensitizer to the individual. The present invention also relates to a device for photodynamic therapy, comprising a permeable reservoir for containing a photosensitizer formulation for skin application and a light source. The light source is a chemiluminescent light source or a light-emitting diode light... |
| Core-shell nanoparticles for thearapy and imaging purposes | 20090191128 | 20090730 |
| The invention relates to nanoparticles coated with an inorganic nanoscale material herein referred to as core-shell nanoparticle, in which the core material has a wider band gap than the shell material. The described core-shell nanoparticles are very suitable for the application in photodynamic therapy due to their enhanced energy transfer ability.
... |
| De novo synthesis of bacteriochlorins | 20090191130 | 20090730 |
| to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.
... |
| Use of photodynamic therapy to enhance treatment with immuno-modulating agents | 20090192071 | 20090730 |
| Methods of enhancing the efficacy and safety of treatment with immuno-modulating agents are provided. The inventive methods combine treatment with immuno-modulating agents with photodynamic therapy (PDT). PDT can be administered before, during or after administration of the immuno-modulating agent. Combination therapy achieves at least the same efficacy as immuno-modulatory therapy in less time, with less immuno-modulating agent and fewer side-effects.
... |
| Water soluble tetrapyrollic photosensitizers for photodynamic therapy | 20090162289 | 20090625 |
| or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.
... |
| Water soluble tetrapyrollic photosensitizers for photodynamic therapy | 20090162289 | 20090625 |
| or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.
... |
| Phthalocyanine dyes and their preparation and use | 20090155177 | 20090618 |
| wherein R1-R8, R9-R12, Me, M, m, n, o and p are as described in the specification, are excellent photosensitizers for the preparation of pharmaceutical compositions for photodynamic therapy or photo diagnostics.
... |
| Novel derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy | 20090149525 | 20090611 |
| The invention relates to derivatives of porphyrin, particularly chlorins and/or bacteriochlorins, which can be used in photodynamic therapy. According to the formulas of the invention, X1, X2, X3, X4, X5, X6, X7, X8, which maybe identical or different, each represent halogen atoms or hydrogen atoms. R1, R2, R3, R4, which may be identical or different, are each selected from the following groups: —OH, amino acids, —OR and —NHR and/or a chlorine atom, wherein R is an alkyl group having between 1 and 12 carbon atoms. The invention also relates to an anticancer and/or antiviral and/or antimicrobial medicament for human or animal use, which contains one or more compounds as the main active ingredient.
... |
| Biologically active methylene blue derivatives | 20080312219 | 20081218 |
| The compounds are biologically active photosensitisers which are strongly photocytotoxic and have application in the areas of photodynamic therapy (PDT), as well as for the diagnosis and detection of medical conditions and related uses in photochemical internalisation, in the production of cancer vaccines, in the treatment and prevention of microbial infections and in photodisinfection or photosterilisation.
... |
| Photosensitizers for photodynamic therapy at infrared excitation | 20080286262 | 20081120 |
| A photosensitizer that is excitable via infrared radiation and is adapted to be used to treat a selected biological target. The photosensitizer comprises a core nanoparticle adapted to convert infrared radiation into a visible light emission, and a coating disposed about the core nanoparticle. The coating contains a light excitable agent that is adapted to be excited by the visible light emission from the core nanoparticle. The photosensitizer can be surface modified with an antibody to make the photosensitizer specific to the biological target that is to be treated. Such surface modified photosensitizer is introduced to the target site and irradiated with infrared radiation.
... |
| Glycosylated carboranylporphyrins and uses thereof | 20080279781 | 20081113 |
| The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity glycosylated carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, and head and neck. The invention is also directed to using these glycosylated carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
... |
| Process for the preparation of porphyrin derivatives as antimicrobial agents by photodynamic therapy (pdt) | 20080281091 | 20081113 |
| There is provided a process for the preparation of 5,15-bis-[4-(3-trimethylammonio-propyloxy)-phenyl]-porphyrin dihalide, wherein the process comprises step (a) of providing 4-(3-bromopropyloxy)benzaldehyde, step (b) of providing dipyrrolmethane, step (c) of reacting the 4-(3-bromopropyloxy)benzaldehyde with the dipyrrol-methane, together with trifluoro acetic acid, in the presence of an oxidation reagent to produce 5,15-bis-[4-(3-bromo-propyloxy)-phenyl]-porphyrin which is purified by Soxhlet extraction from the adsorbed state on a bed of alumina under highly controlled conditions; and step (d) of reacting the 5,15-bis-[4-(3-bromo-propyloxy)-phenyl]-porphyrin with trimethylamine in the presence of dry dimethylformamide to produce 5,15-bis-[4-(3-trimethylammonio-propyl-oxy)-phenyl]-porphyrin dibromide. In a preferred embodiment, the process further comprises step (e) of passing the 5,15-bis-[4-(3-trimethylammonio-propyloxy)-phenyl]-porphyrin dibromide produced in step (d) through an anion exchanger to produce 5,15-bis-[4-(3-trimethylammonio-propyloxy)-phenyl]-porphyrin dichloride. There is provided a process for the preparation of 5,15-bis-(4-{3-[(3-dimethylamino-propyl)-dimethyl-ammonio]-propyloxy}-phenyl]-porphyrin dihalide.
... |
| Photosensitizer formulations for topical applications | 20080274169 | 20081106 |
| Highly flexible penetrating liposomal carrier systems are formulated with enhanced skin penetration properties. These specialized formulations of highly flexible penetrating liposomal delivery systems comprise one or more phospholipids, lysophosphatides and hydrophobic photosensitizer. This new formulations can squeeze liposomal particles through intercellular regions of stratum corneum as intact structures, and, in this way, deliver encapsulated photosensitizer to the epidermis, dermis, hypodermis and surroundings. The penetrating liposomal formulation provides therapeutically effective amounts of the hydrophobic photosensitizer through topical application with better skin penetration thus improving drug targeting and the efficacy of photodynamic therapy (PDT).
... |
| Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy | 20080275232 | 20081106 |
| The present invention provides a process of preparation of naphthochlorins and other chlorins with annelated ring systems useful for photodynamic therapy and the compounds themselves. The method for producing naphthochlorin compounds include contacting compounds such as meso-(2′-hydroxymethyl)phenyl porphyrin or meso-(2′-N,N,N-trialkylaminomethyl)phenyl porphyrin precursors with at least one acid catalyst at sufficient temperature for a sufficient time to yield the desired conversion. In a similar manner chlorins possessing annelated ring systems may be made from compounds such as meso-(2′-hydroxymethyl)aryl porphyrins or meso-(2′-N,N,N-trialkylaminomethyl)phenyl porphyrin. The procedures described herein provide new routes for synthesizing naphthochlorins and chlorins with annelated ring systems.
... |
| Light source for fluorescence diagnosis and photodynamic therapy | 20080269576 | 20081030 |
| Disclosed herein is a light source device for fluorescence diagnosis and photodynamic therapy comprising: a plurality of light source means having a wavelength range different from each other and providing selected light; a light path coupling means coupling light emitted from the light source means to the incident direction of a light guide; a filtering means selectively transmitting the emitted light based on the wavelength; and a switching device that is directed to an opening/closing means, established at a long distance to be controlled by a remote control device and selecting the kinds of light sources of the light source means to change the modes of the light. Accordingly, the device simplifies the configuration by excluding elements causing errors in the process of fluorescence diagnosis in... |
| Waveguide connection device | 20080269845 | 20081030 |
| A connector for interconnecting a waveguide with a light component (e.g., another waveguide) for allowing light communication therebetween. Assemblies for connecting a waveguide can be formed with the connector. In one embodiment, the connector is employed for connecting to a waveguide useful in performing medical applications such as provision of photodynamic therapy.
... |
| Device for treatment of blood vessels using light | 20080269846 | 20081030 |
| Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve... |
| Biologically active methylene blue derivatives | 20080261960 | 20081023 |
| The compounds are biologically active photosensitisers which are strongly photocytotoxic and have application in the areas of photodynamic therapy (PDT), as well as for the diagnosis and detection of medical conditions and related uses in photochemical internalisation, in the production of cancer vaccines, in the treatment and prevention of microbial infections and in photodisinfection or photosterilisation.
... |
| Photodynamic therapy device | 20080255549 | 20081016 |
| The invention described herein is an apparatus for performing photodynamic therapy comprising: a waveguide, a light source in communication with one end of the waveguide, a photodynamic tip in communication with another end of the waveguide wherein the photodynamic tip is designed to be securely but removably attached to a scaling tip of a scaler and the apparatus delivers light in a desired illumination pattern and in at least one predetermined wavelength to activate a photosensitizing composition for the killing of microbes. The invention also includes a method for using the apparatus in conjunction with a scaler to perform sonophotodynamic therapy and a method for making the apparatus.
... |
| Use of green porphyrins to treat neovasculature in the eye | 20080241232 | 20081002 |
| Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.
... |
| Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof | 20080233047 | 20080925 |
| The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity halogenated, carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these halogenated, carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
... |
| Nanoparticles for two-photon activated photodynamic therapy and imaging | 20080233051 | 20080925 |
| The present invention provides organically modified silica (ORMOSIL) nanoparticles into which have been incorporated two-photon absorption dye molecules. The two photon absorption dye displays a unique aggregation induced fluorescence enhancement behavior. As a result ORMOSIL nanoparticles with high amounts of the dye can be prepared. These particles can be used for imaging. In one embodiment, the nanoparticles can additionally have incorporated therein a photosensitizer. The photosensitizer can be activated by intraparticle fluorescence resonance energy transfer (FRET) from the dye aggregates resulting in enhanced fluorescence and singlet oxygen generation from photosensitizer under two-photon excitation conditions. Such nanoparticles can be used for photodynamic therapy applications.
... |
| Agent for photodynamic therapy containing porous silicon and method of quantitative measurement of reactive oxygen species produced therefrom | 20080226743 | 20080918 |
| The present invention relates to an agent for photodynamic therapy (PDT) containing porous silicon (PSi) and a method of quantitative measurement of reactive oxygen species (ROS) produced therefrom. Particularly, it is expected that the present invention will contribute to the development of cancer treatment without side effects by suggesting PSi, a safe and reliable new cancer drug that can destroy cancer cells through generating sufficient heat with little ROS produced if the PSi is used as nanobomb for a new PDT that kills cancer cells with heat or explosion. In addition, it is expected that the present invention will provide a reliable and reproducible method for quantitative measurement of a very small amount of ROS produced therefrom through an XRD analysis.
... |
| Treating cancer using electromagnetic fields in combination with photodynamic therapy | 20080221630 | 20080911 |
| A light generating circuit is implanted in a subject's body and aimed at a target region such as a tumor. A photosensitizer is introduced into the target region, and an AC electric field is induced in the region. The field causes the light generating circuit to generate light, which activates the photosensitizer; and at certain field strengths and frequencies, the field itself has a beneficial effect. The beneficial effects of the field and the activated photosensitizer are thereby obtained simultaneously.
... |
| System and method for monitoring photodynamic therapy | 20080221647 | 20080911 |
| A system and method for monitoring photodynamic therapy of a target tissue, where the target tissue contains a photosensitizing substance, include a first light source configured to deliver light to the target tissue, the first light source having a wavelength capable of exciting the photosensitizing substance. An ultrasonic transducer receives photoacoustic signals generated due to optical absorption of light energy by the target tissue, and a control unit in communication with the ultrasonic transducer reconstructs photoacoustic tomographic images from the received photoacoustic signals to provide an indication of optical energy deposition due to the photosensitizing substance in the target tissue.
... |
| Combined photocoagulation and photodynamic therapy | 20080221648 | 20080911 |
| A method for treating a lesion of an animal, the animal having at least one vessel that carries blood to the lesion, comprising locating the vessel, administering a composition comprising a photodynamic agent, applying energy to the vessel to photocoagulate the vessel and thereby reduce the rate at which the treatment composition exits said lesion and applying energy to said lesion, of a type and an amount sufficient to excite the photodynamic agent, causing the lesion to undergo photodynamic therapy. Preferably, a dye that is both a fluorescent dye and a radiation absorbing dye, such as indocyanine green dye, is added to the treatment composition to allow (a) confirmation of the presence of the treatment composition b the lesion to be detected by fluorescent angiography and... |
| Activatable photodynamic therapy agents | 20080193431 | 20080814 |
| The present invention relates to the field of conjugates comprising a substrate which is attached to at least one photoactivatable killing agent and at least one first quencher, and methods for their use. More particularly, the present invention relates to photodynamic therapy agents. The invention further relates to methods for decontaminating blood and methods for treating cancer or viral infection in a subject using the conjugates of the present invention.
... |
| Photosensitizer formulations and their use | 20080195032 | 20080814 |
| A new treatment regime is presenter using a low concentration formulation at a low dosage of hydrophobic photosensitizers (PS) that shows improved pharmacokinetics and an effective method for photodynamic therapy (“PDT”). The new formulation has better pharmacological effect compared to standard photosensitizer formulation with standard dosage. It was found that PDT treatments using the disclosed low concentration formulations provide for more accurate, more efficient and more convenient dosing. It was found that the inventive formulation; (1) reduces the time for a therapeutically effective level of photosensitizer to accumulate in diseased tissue; and, (2) reduces the time for achieving a sufficient ratio of photosensitizer in diseased tissue vs. healthy tissue. As a result, the formulation of the invention reduces the time interval between PS application/administration and irradiation... |
| Methods and compositions for treatment of ocular neovascularization and neural injury | 20080176953 | 20080724 |
| Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.
... |
| Apparatus and method for photodynamic diagnosis and therapy of skin diseases and light source system thereof | 20080147053 | 20080619 |
| The present invention provides an apparatus and method for photodynamic diagnosis and therapy of skin diseases and a light source system thereof that can improve the efficiency of skin diagnosis by accurately analyzing skin conditions using fluorescence and white light simultaneously and further carry out fluorescent diagnosis and photodynamic therapy in the same skin region simultaneously. The apparatus for photodynamic diagnosis and therapy of skin diseases of the present invention includes: a camera head including a case having a view hole, provided in front thereof, to be in contact with a skin region, a white light source provided so as to irradiate a white light from the inside of the case through the view hole onto the skin region, a digital color TV camera provided in... |
| Conjugates of rgd peptides and porphyrin or (bacterio) chlorohyll photosynthesizers and their uses | 20080138278 | 20080612 |
| Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and normeoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.
... |
| Photosensitive compounds | 20080139804 | 20080612 |
| To provide a novel photosensitive compound which is useful for a photodynamic therapy, an agent for the photodynamic therapy containing the same and a method for producing the same. A compound represented by the following formula 1 or pharmaceutically acceptable salts thereof.
... |
| Use of nanoparticles in the photodynamic treatment of tumors and non-destructive testing | 20080139993 | 20080612 |
| A method for generating light intensity inside a tumor to aid in the treatment of diseases such as cancer is disclosed. The light is generated inside the body to perform a modified photodynamic therapy treatment (PDT) that allows treatment of body regions that are inaccessible by normal PDT procedures. In addition, the use of two spatially and temporally coincident treatment modalities, i.e. radiation and PDT, have the potential for significant biological synergy in the tumor.
... |
| Carboranylporphyrins and uses thereof | 20080131376 | 20080605 |
| The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT), and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing porphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
... |
| Multi-modal scanning confocal adaptive-optic macroscope system and associated methods | 20080119832 | 20080522 |
| In some embodiments, the present disclosure is directed to a multi-modal, scanning, confocal, adaptive-optic macroscope system and related methods of use. Embodiments of the present disclosure improve upon existing photodynamic therapy methods and compete with more invasive oncology procedures (such as surgery, radiation, and/or chemotherapy) by providing deeper light penetration within the human body, giving medical personnel the ability to treat forms of cancer previously untreatable with existing photodynamic therapies, and with less damage to healthy tissue than current procedures. Embodiments of the present disclosure may be used for other medical purposes including internal artery and vein cauterizing (photo-coagulation), laser pulse induced sonication for dissolving kidney stones, removal of birth marks or tattoos, and/or for photo-biostimulation.
... |
| Use of an agent that restores tissue perfusion and oxygenation | 20080113901 | 20080515 |
| The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations... |
| Use of an agent that restores tissue perfusion and oxygenation | 20080107637 | 20080508 |
| The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations... |
| Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins | 20080096857 | 20080424 |
| The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.
... |
| Photodynamic therapy apparatus | 20070299485 | 20071227 |
| Provided is the photodynamic therapy apparatus which is capable of detecting damage to the healthy part existing at a shallower part of a living body than the lesioned part so as to prevent disorder of the healthy part. The photodynamic therapy apparatus 10 is the photodynamic therapy apparatus 10 for treating the lesioned part existing at a deep part of a living body, using a light-sensitive substance which is activated by a light having a peak intensity within a predetermined range, but almost not activated by a light having the peak intensity out of the predetermined range, having: an irradiation device 12 which irradiates, onto the living body, pulsed light having wavelength which is capable of activating the light-sensitive substance; a detection device 14 which detects... |
| Continuous low irradiance photodynamic therapy system and method | 20070288071 | 20071213 |
| Systems and methods are providing for treating a patient with continuous low irradiance photodynamic therapy. A disclosed method includes applying a photosensitizer to the patient; applying a conformable skin facing light applicator to the patient; and providing continuous low irradiance photodynamic therapy through the light applicator. A disclosed system includes a light applicator having a fiber optic cloth. The light applicator is conformable so that it can be worn against a patient's skin and the fiber optic cloth has a two dimensional surface that emits light in a direction toward a patient's skin. In this aspect, the power of the light emitted from the two dimensional surface in a direction toward a patient's skin is less than or equal to about 5 mW/cm2.
... |
| Porphyrin derivatives and their use in photodynamic therapy | 20070281915 | 20071206 |
| wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilising solutions comprising a compound of the invention, and the use thereof, are also disclosed.
... |
| Apparatus for photodynamic therapy | 20070260296 | 20071108 |
| A therapeutic bed 1 for photodynamic therapy has a ground engaging base portion 2 with a patient support platform 3. A cover 4 is hingedly mounted on this base portion 2 and cooperates with the base portion 2 to form a patient treatment compartment 6 within which a patient 7 is fully bathed in light from LED panels 8 arranged about the patient support platform 3 to direct light of a preselected wavelength at the patient 7. The wavelength of the light corresponds to the peaks of absorption of an associated photosensitive agent administered to the patient 7 which has an affinity for malignant cells.
... |
| Illuminator for photodynamic therapy | 20070249716 | 20071025 |
| An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic ballasts. Adjustment of the ballast voltage controls the output power of the tubes. The tubes are supported by a sheet-metal or plastic housing and are covered by a polycarbonate shield which directs cooling airflow within the unit and prevents glass-patient contact in the event of tube breakage. An aluminum reflector located behind the tubes increases both the output irradiance and the uniformity of the output distribution. The spacing of the U-shaped tubes is varied to increase... |
| Therapeutic light source and method | 20070233209 | 20071004 |
| A therapeutic light source, for example for photodynamic therapy (PDT), comprises an air-cooled array of LED's (Lx,y), the air being vented in the vicinity of the array. The array may be mounted at the distal end of a hand piece suitable for invasive therapy. The LED's may be coupled to a light guide (W, L). The emission spectra of the LED's may be substantially limited to the range 550 to 660 nm, and preferably to one of the ranges 590 to 640 nm, 560 to 644 nm, 650 to 660 nm, and 550 to 570 nm. The therapeutic light source may comprise a non-planar array of light-emitting diodes L conforming with the shape of an external area to be treated or diagnosed. The therapeutic light source... |
| 5-aminolevulinic acid salts and their use | 20070225518 | 20070927 |
| wherein RY is an organic acid moiety; Y is selected from the group consisting of a sulfonic acid residue, mono- or di-phosphoric acid residue, mono- or di-carboxylic acid residue and R is selected from the group consisting of saturated, unsaturated, straight or branched C2-C20 chains, aryl, aralkyl or naphthyl. In preferred embodiments, RY is selected from benzenesulfonic acid (besylate), 2-naphthalene sulfonic acid (napsyate), p-toluenesulfonic acid (tosylate), diethyl phosphate, dibenzyl phosphate, di-(2-ethylhexyl) phosphate, caproic or stearic acids. The invention also provides methods for preparing the ALA salts of the invention, pharmaceutical compositions containing the ALA salts of the invention, and use of the ALA salts of the invention in photodynamic therapy (PDT).
... |
| Nanoparticle based photodynamic therapy and methods of making and using same | 20070218049 | 20070920 |
| A novel method for cancer treatment that combines radiotherapy and photodynamic therapy (PDT). More particularly, luminescent nanoparticles with attached photosensitizers, such as porphyrins, are used as a new type of agent for photodynamic therapy. Upon exposure to ionizing radiation, light will emit from the nanoparticles to activate the photosensitizers; as a consequence, a singlet oxygen is produced to augment the killing of cancer cells by ionizing radiation. No external light is necessary to activate the photosensitizing agent within tumors. The combination of radiotherapy and PDT is more efficient than either used alone.
... |
| Therapeutic applications of aminolevulinate synthase | 20070218465 | 20070920 |
| Systems and methods for increasing protoporphyrin IX accumulation in a target cell population using aminolevulinate synthase variants. Aminolevulinic acid-mediated photodynamic therapy is a promising approach to treating dysplasic disorders such as cancer and atherosclerosis, but is limited by the lack of a means to deliver optimal quantities of aminolevulinic acid selectively to the target cells, and thereby ensure the best therapeutic response. The disclosed invention provides a means for enhancing the natural production of aminolevulinic acid selectively within target cells to levels predetermined to give an optimal therapeutic response, and is expected to lead to increased efficacy of treatment, possibly broadening the scope of diseases treatable by photodynamic therapy considerably. The disclosed invention is also amenable to patient specific therapy, meaning that a patient's target cells... |
| Light emitting panel for medical applications | 20070195548 | 20070823 |
| A light emitting panel is disclosed for medical applications including photodynamic therapy and photo bio-stimulation. The light emitting panel utilizes high intensity light emitting diodes (LEDs) as its light source and side-emitting optical fibers for light delivery.
... |
| Ethylene glycol esters as photoactive agents | 20070191329 | 20070816 |
| R2 is vinyl or a derivative form thereof.
... |
| Methods and compositions for treating conditions of the eye | 20070191917 | 20070816 |
| Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an ansamycin analog or heat shock protein 90 inhibitor, for example, 17-allylamino-17-demethoxygeldanamycin.
... |
| Methods and devices for epithelial protection during photodynamic therapy | 20070173913 | 20070726 |
| Methods for preventing damage to epithelial tissue during PDT induced using a photosensitizing agent or pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control photoactivation of the photoactive species to protect the epithelial tissue. In one embodiment, epithelial tissue surrounding a targeted treatment site can be protecting by decreasing the oxygen-content in the tissue, thereby preventing the conversion of the photosensitizer into the phototoxic species in the epithelial tissue.
... |
| Novel uses of porphyrin compounds | 20070167619 | 20070719 |
| The invention provides the use of a compound of Formula (I), or metallated derivative thereof, in the preparation of a medicament for killing or attenuating the growth of microorganisms by a method which does not comprise exposing the compound to a photodynamic therapy light source or a sonodynamic therapy ultrasound source Formula (I) wherein X1, X2, X3, X4, Yi, Y2, Y3, Y4 and Z have meanings given in the description. Preferably, the microorganisms are selected from the group consisting off bacteria, mycoplasmas, yeasts, fungi and viruses.
... |
| Removal of fat cells by pdt | 20070154538 | 20070705 |
| A non-surgical, minimally invasive PhotoDynamic Therapy (PDT) method for destruction of undesirable fat cells in the body, which cause obesity, obesity related health problems, and undesirable body contours. In this method photosensitizing agents are formulated into a liposomal formulation or into other delivery means for administering the drug systemically, directly by injection and/or topical application. The photosensitizing formulation is selectively targeted at adipose tissue in the subcutaneous layer. Photosensitized adipose cells are illuminated with a predetermined wavelength of light energy known to initiate a photo cytotoxic effect. The light energy for photoactivation of the photosensitizing agent may be applied interstitially through optical fibers with or without a diffuser tip. Alternatively, a photosensitizing agent is selected to have an activating wavelength which permits external irradiation through the... |
| Water soluble tetrapyrollic photosensitizers for photodynamic therapy | 20070149497 | 20070628 |
| or a pharmaceutically acceptable derivative thereof, wherein R1-R8 and R10 are various substituents and R9 is substituted or unsubstituted —CH2CH2CON(CH2CON(CH2COOH)2)2; or —N(CH2COOH)2. The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.
... |
| Method for delivering hydrophobic drugs via nanocrystal formulations | 20070134340 | 20070614 |
| This invention provides nanocrystals or polymer doped nanocrystals of hydrophobic drug molecules as stably dispersed in an aqueous system which are prepared without stabilizers like surfactants and the like. In one embodiment, the drug is a tetra-pyrrole compound. An example is the hydrophobic photosensitizing anticancer drug 2-devinyl-2-(1-hexyloxyethyl)pyropheophorbide (HPPH). Pharmaceutical compositions comprising nanocrystals or polymer doped nanocrystals of hydrophobic drugs can be used for therapeutic purposes. For example pyropheophorbides such as HPPH can be used for photodynamic therapy. Drug efficacy of these nanocrystals were found to be comparable with that of same drug formulated in conventional delivery vehicles under in vitro and in vivo conditions.
... |
| Photodynamic therapy for the treatment of prostatic conditions | 20070099887 | 20070503 |
| The present invention relates to a photodynamic method of treating prostatic disorders such as BPH. The method comprises: (i) delivering photosensitizer directly into prostatic tissue of a patient suffering from or suspected of suffering from a prostatic disorder; and (ii) irradiating the prostatic tissue with a light at a wavelength appropriate to activate the photosensitizer.
... |
| Radiation enhancement agent for x-ray radiation therapy and boron neutron-capture therapy | 20070093463 | 20070426 |
| Low toxicity halogenated carborane-containing tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention also includes methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET using these halogenated carborane-containing tetraphenylporphyrin compounds.
... |
| Drug delivery systems for photodynamic therapy | 20070086973 | 20070419 |
| The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.
... |
| Use of green porphyrins to treat neovasculature in the eye | 20070087046 | 20070419 |
| Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.
... |
| Combined oct catheter device and method for combined optical coherence tomography (oct) diagnosis and photodynamic therapy (pdt) | 20070073364 | 20070329 |
| In a catheter device and a method for in vivo activation of a photosensitizing drug in a vessel, endovascular tissue, and/or intraluminal tissue, a catheter carrying both an optical coherence tomography (OCT) lens, from which OCT imaging light is emitted, and a photodynamic therapy (PDT) lens from which photosensitizing drug-activating light is emitted, is inserted into a vessel containing a lesion to be treated. A photosensitizing drug is caused to be placed in the vessel as well, such as in the form of a coating on a stent or a coating on an exterior of a balloon carried by the catheter. Light is emitted from the PDT lens to activate the photosensitizing drug while light is simultaneously emitted from the OCT lens to obtain an OCT... |
| Substituted metal-phthalocyanines, their preparation and the use thereof | 20070066513 | 20070322 |
| The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and/or in the diagnosis, as well as for blood and blood derivatives sterilization.
... |
| Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents | 20070059316 | 20070315 |
| Provided herein are conjugates, kits, articles of manufacture and methods for detection, diagnosis and treatment by photodynamic therapy of certain undesired biological substrate targets, including, but not limited to bacteria, viruses, and other pathogenic microorganisms, tumors and hyperproliferative tissue. In particular, the conjugates provided include a fluorophore or photosensitizer linked to a targeting moiety and a quenching agent in such a way that activation of the fluorophore or the photosensitizer is quenched unless the targeting moiety is bound to a target, whereupon the quenching agent dissociates or moves away from the photosensitizer, enabling activation of the photosensitizer upon irradiation with light of a suitable wavelength.
... |
| Porphyrin compound containing biotinyl group and use thereof | 20070042439 | 20070222 |
| wherein Por represents a porphyrin residue optionally forming a metal complex; Bi represents an optionally substituted biotinyl group; and A represents a C1-C20 hydrocarbyl group, or a heterohydrocarbyl group having 1-5 heteroatoms selected from a group consisting of oxygen, sulfur, and nitrogen, and having 1-20 atoms in total; a method for purifying hemoprotein which use the porphyrin compound; a hemoprotein labeling reagent; a diagnostic agent for hemoprotein associated diseases which use the porphyrin compound; and a therapeutic agent for photodynamic therapy.
... |
| Photodynamic therapy irradiation system for the treatment of superficial hyperproliferative tissue growth | 20070032845 | 20070208 |
| A device and method is described for photodynamic therapy (PDT) to treat hyperproliferative tissue growth in an underskin area within a few centimeters of the skin surface that is not accessible by conventional topical irradiation. The device comprises a plate having an array of openings with hollow micro-needles mounted therein that extend to a specified length on each side. Optical fibers are individually threaded through the micro-needles from the side opposite the treatment area and may be kept together as a bundle for attachment to a laser radiation source. The optical fibers have output ends made to provide a uniform radiation pattern to the underlying tissue. A photosensitizer is administered either systemically or locally and allowed a sufficient time to diffuse into the area of treatment.... |
| Methods for treating ocular neovascular diseases | 20070027101 | 20070201 |
| Disclosed herein are methods for treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy.
... |
| Use of photosensitisation | 20070020241 | 20070125 |
| A composition comprising a conjugate of a photosensitiser and a bacteriophage is provided. The conjugate may be used to kill bacteria, particularly MRSA, EMRSA, VRSA, hetero-VRSA or CA-MRSA in a targeted method of photodynamic therapy.
... |
| Dendrimer-photosensitizer complexes for medical applications | 20060292112 | 20061228 |
| A method for enhanced Photodynamic Therapy (PDT) treatments by applying dendrimer-photosensitizer complexes to bring multiple photosensitizer moieties to a treatment site is provided. The most benefit is derived for treatments using systemic introduction of the photosensitizer formulation. Photosensitizers are covalently coupled to the peripheral bonding places of dendrimers, using labile bonds which are breakable in preference over bonding within either photosensitizer or dendrimer, and the photosensitizers are separated from the complexes in one or more successive cycles. Tetrapyrroles are the photosensitizers employed. In one embodiment the complex is also bound to an antibody or antibody fragment, which aids in targeting the complex to a desired treatment site. After introduction into a patient, the photosensitizers are controllably released, at the treatment site, from the complexes by either... |
| Amphiphilic trisulfonated porphyrazines for photodynamic applications in medicine | 20060282038 | 20061214 |
| Disclosed herein are novel trisulfonated tribenzo-mononahptho-porphyrazines, processes for making them and their application as improved photosensitizing drugs for the treatment of various medical conditions by photodynamic therapy (PDT). These water-soluble amphiphilic porphyrazines are substituted with different alkylyl, aryl, aminoalkyl and aminoaryl groups, with or without carboxyl moeity.
... |
| Photodynamic therapy equipment, method for controlling photodynamic therapy equipment and method of photodynamic method | 20060282132 | 20061214 |
| Photodynamic therapy equipment 1 for treating lesioned part by using a photosensitive substance, which is activated by the light having a peak intensity of a predetermined range but is almost not activated by the light having the peak intensity out of the predetermined range, equipped with an irradiation means 13 irradiating into the body a pulsed light of the wavelength having the potential for activating the photosensitive substance, and a control means 22 controlling the peak intensity of the light irradiated by the irradiation means, and the control means 22 allows the irradiation means 13 to irradiate the light having the high peak intensity in order that the light arriving at the deep-lying lesioned part 41 is to achieve the peak intensity of the predetermined range.... |
| Switched photodynamic therapy apparatus and method | 20060282136 | 20061214 |
| A photodynamic therapy apparatus and method in which (1) phototoxic drug is supplied to a target tissue, (2) delivery of drug activating light to the target tissue through probes is controlled by sequential selection of operation of the probes, (3) an automatic radiance probe is used for efficient optical characterization of the target tissue, and (4) an optical dose is monitored by sequential selection of probes as transmitters and receivers.
... |
| Use of an agent that restores tissue perfusion and oxygenation | 20060276374 | 20061207 |
| The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations... |
| Hair growth | 20060265028 | 20061123 |
| It has been discovered that photodynamic therapy (PDT) can stimulate an increase in hair count numbers and restore hair growth in areas of hair loss. A method according to the present invention comprises: a) administering an effective and/or sufficient amount of a photosensitizer to the target skin; b) irradiating the target skin with energy comprising one or more wavelength capable of activating said photosensitizer for a time period sufficient to activate the photosensitizer, wherein there is an increase in hair count numbers in the treated area. In one aspect of the present invention, there is a 2% or more increase in the number of terminal hairs within 3 months.
... |
| Photodynamic therapy for ocular neovascularization | 20060258629 | 20061116 |
| Method, apparatuses and systems are provided for the photodynamic treatment of feeder vessels associated with aberrant choroidal neovasculature.
... |
| Antibody-targeted photodynamic therapy | 20060231107 | 20061019 |
| Disclosed are photosensitizer-antibody conjugates and methods for making such conjugates. Also disclosed are methods for using photosensitizer-antibody conjugates in photodynamic therapy to treat subjects with various diseases.
... |
| Photodynamic therapy utilizing multiple duty cycle light modulation | 20060234959 | 20061019 |
| A method of photodynamic disruption of target cells within a target cell site wherein the target cells are associated with one or more of a sterilization procedure, a biofilm eradication procedure, a sterilization procedure of a medical prosthesis, a treatment of an infection at a tissue site, eradication of cancer cells and a fluid or food decontamination process. Surface acting agents such as benzalkonium chloride or polymyxin B sulfate or both may be utilized. A controllable light source capable of delivering light at a plurality of duty cycles is utilized to cause photoactivation of the photosensitive material resulting in degradation of target cells within the site.
... |
| Enhanced occlusive effect photodynamic therapy | 20060229284 | 20061012 |
| This invention discloses methods of treating neovasculature diseases of the eye through the administration of a photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate the photosensitizing agent to occlude one or more vessels in the neovasculature for an extended period of time. Diseases treatable under this invention, include, for example: diabetic retinopathy; macular degeneration; subfoveal choroidal neovascularization, malignant uveal melanomas and other maladies of the human or animal eye or body.
... |
| Agents and methods for enhancing photodynamic therapy | 20060223750 | 20061005 |
| A chemical conjugate for administration to a patient undergoing photodynamic therapy includes a photoactive compound coupled to a leakage reducing agent that is structured to reduce leakage of the photoactive compound from a patient's vasculature. The leakage reducing agent may be a bulking agent to reduce, for example, sterically reduce, the permeability of the photoactive compound through the blood vessel, or it may be a ligand that binds to endothelial cells of a patient's choriocapillaries. The conjugate may be used in methods of reducing secondary damage associated with photodynamic therapy.
... |
| Micelle delivery system loaded with a pharmaceutical agent | 20060216342 | 20060928 |
| The invention is directed to an improved drug delivery system that includes a micelle, comprising polyethylene glycol and a lipid component, and a pharmaceutical agent dispersed in the lipid component. The delivery system may also include a targeting ligand. The micelle delivery system of the invention is capable of stabilizing, inter alia, poorly soluble pharmaceutical agents and increasing their delivery efficacy. Appropriate pharmaceutical agents useful in the system of the invention include anti-inflammatory agents, agents for photodynamic therapy, anti-tumor agents, anti-neoplastic agents, anti-metastatic agents, and imaging agents, as well as hydrophobized derivatives thereof. Specifically, the pharmaceutical agent can be porphyrin, chlorine-6-trimethyl ester, tamoxifen, paclitaxel, 1,3-bis(2-chloroethyl)-1-nitrosourea, camptothecin, ellipticine, rhodamine, dequalinium, diphenylhexatriene, vitamin K3, diethylene triamine pentaacetic acid, or a functional derivative thereof. The micelles in the system... |
| Chlorin and bacteriochlorin-based difunctional aminophenyl dtpa and n2s2 conjugates for mr contrast media and radiopharmaceuticals | 20060204437 | 20060914 |
| where R1, R2, R2a R3, R3a R4, R5, R5a R6, R7, R7a, and R8 cumulatively contain at least two functional groups that will complex or combine with an MR imaging enhancing element or ion. The compound is intended to include such complexes and combinations and includes the use of such compounds for MR imaging and photodynamic therapy treatment of tumors and other hyperproliferative tissue.
... |
| Methods and compositions for treating conditions of the eye | 20060204504 | 20060914 |
| Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.
... |
| Porphyrin-based compounds for tumor imaging and photodynamic therapy | 20060198783 | 20060907 |
| This invention describes a first report on the synthesis of certain 124I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy (PDT). The development of tumor imaging or improved photodynamic therapy agent(s) itself represent an important step, but a dual function agent (PET imaging and PDT) provides the potential for diagnostic body scan followed by targeted therapy.
... |
| De novo synthesis of bacteriochlorins | 20060194960 | 20060831 |
| to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.
... |
| Wound treatment device for photodynamic therapy and method of using same | 20060173514 | 20060803 |
| The invention relates to a light emitting treatment device including one or more light members, which are configured to emit light energy for the purpose of performing localized photodynamic therapy at a targeted field. The light members may be disposed in a substantially uniform array and be configured to emit energy in a substantially uniform pattern. The light treatment device has a self-contained energy supply. The light emitting treatment device may be controlled to deliver one or more various light doses and dose rates at various light frequencies per treatment. The treatment device may be made of a polymeric material configured to conform to a body surface. The treatment device may contain the photosensitizer. The light emitting treatment device may further include a heat dissipating layer... |
| Hydrophobic photosensitizer formulations for photodynamic therapy | 20060159740 | 20060720 |
| Pharmaceutical liposomal formulations for photodynamic therapy are presented, which are stable in storage as liquid formulations, comprise a hydrophobic photosensitizer and one or more synthetic phospholipids. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. The formed liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. In the present formulation the size of the liposomal vehicles and their content of a therapeutically effective amount of the photosensitizing agent remain unchanged over storage times of a year or more, thus making the liquid formulations commercially viable. Being stable in the liquid state also makes them easy to store, and easier to use for doctors and patients. They can be prepared in a ‘factory setting’ delivered to practitioners in a liquid state and... |
| Water-soluble anionic bacteriochlorophyll derivatives and their uses | 20060142260 | 20060629 |
| The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.
... |
| Sensitized online bold-mri imaging method | 20060135868 | 20060622 |
| An online Blood Oxygenation Level-Dependent (BOLD)-magnetic resonance imaging (MRI) method for functional clinical guidance or monitoring a therapeutic modality involving treatment by a sensitizer which, upon excitation by the appropriate sensitizing radiation, initiates local oxygen consumption, comprising: (i) generating a BOLD-weighted MR-image of the target region of interest within the patient's body (time t0); (ii) administering said sensitizer to the patient; (iii) irradiating the target region while the patient is subjected to continuous MR imaging; (iv) generating a sole or a plurality of T2* weighted sequential BOLD MR-images during and/or after irradiation (time t); (v) processing the data generated at time t0 and time t and generating a color-coded difference or ratio map on a pixel by pixel basis; and (vi) analyzing the processed data. The... |
| Methods and apparatuses for positioning within an internal channel | 20060135870 | 20060622 |
| Methods and apparatuses for positioning medical devices onto (or close to) a desired portion of the interior wall of an internal channel, such as for scan imaging, for photodynamic therapy and/or for optical temperature measurement. In one embodiment, a catheter assembly has a distal portion that can be changed from a configuration suitable for traversing the internal channel to another configuration suitable for scan at least a spiral section of the interior wall of an internal channel, such as an artery. In one example, the distal portion spirals into gentle contact with (or close to) a spiral section of the artery wall for Optical Coherence Tomography (OCT) scanning. The spiral radius may be changed through the use of a guidewire, a tendon, a spiral balloon, a... |
| Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy | 20060127471 | 20060615 |
| Pharmaceutical pegylated liposomal formulations for photodynamic therapy are presented. The pegylated liposomal formulation provides therapeutically effective amounts of the photosensitizer for intravenous administration. At least one of the phospholipids in the liposomes has been linked with poly ethylene glycol (PEG) as an integral part of the phospholipids. The formed pegylated liposomes contain the hydrophobic photosensitizer within the lipid bilayer membrane. Pegylation of liposomes carrying the hydrophobic photosensitizer helps to maintain the drug level within the therapeutic window for longer time periods and provides the drug a longer circulating half life in vivo. Further the pegylated formulation of hydrophobic photosensitizers shows improved pharmacokinetics over standard non-liposomal formulations thus enhancing the efficacy of PDT with the pegylated liposomal formulations.
... |
| Oxo-bacteriopyropheophorbide-a carboxylic acid and esters thereof | 20060111565 | 20060525 |
| where R is H or lower alkyl of 1 through 12 carbon atoms. In general, the compounds of the invention are 132-Oxo-bacteriopyropheophorbide-a carboxylic acid and C1-C12 alkyl esters thereof. A method for the preparation of the carboxylic acid compounds of the invention includes the step of reacting bacteriopyropheophorbide-a alkyl ester with lithium hydroxide in tetrahydrofuran and water. A method of the invention for the preparation of the C1-C12 alkyl ester compounds of the invention includes the steps of reacting bacteriopyropheophorbide-a alkyl, especially methyl, ester with lithium hydroxide in tetrahydrofuran and water to obtain 132-Oxo-bacterio-pyropheophobide-a carboxylic acid followed by reacting the carboxylic acid with an acid chloride producing reagent to obtain the 132-Oxo-bacterio pyropheophobide-a acid chloride (compound 5) and reacting the 132-Oxo-bacterio pyropheophobide-a acid chloride with a... |
| Device and method for photodynamic therapy of the nasopharyngeal cavity | 20060111762 | 20060525 |
| A device/system and method for the delivery of light to the nasopharyngeal cavity in a controlled and reproducible manner using at least one optical fiber having a linear diffusing tip, a spherical diffusing tip, or a bare cut end is disclosed. A positioning device may have one or two flexible guide tubes that are attached to a preformed shaped base that is introduced into the nasopharyngeal cavity to guide and position the optical fibers and/or detector(s). The optical fibers are enclosed within shielding tubes which are inserted into the guide tubes. The optical fibers may be further moved within the shielding tube so as to adjust the amount of output light. Also included within the guide tube is a light detector that monitors, detects, and measures... |
| Photodynamic therapy light source | 20060106435 | 20060518 |
| A photodynamic therapy light source for treating skin conditions of a patient is disclosed which has a light source (10), a filter wheel (24), a light guide (60), and a control unit (40) for controlling the source. A spectral analyser (80) is included for analysing the spectrum received from a patient, and a camera (70) is also provided for taking images of the patient so that before and after treatment images can be taken for comparison purposes and for further diagnosis. A filter wheel (24) is provided which includes a number of filter elements (24′) for selectively enabling a particular bandwidth of illumination to be provided. The illumination from the unit (10) can be modulated so that a cyclic treatment of a period in which illumination... |
| Photodynamic therapy treatment for eye disease | 20060088530 | 20060427 |
| This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.
... |
| Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy | 20060088584 | 20060427 |
| Pharmaceutical liposomal formulations are described for photodynamic therapy comprising a, hydrophobic porphyrin photosensitizer, a monosaccharide and one or more synthetic phospholipids, which are stable in storage especially through freeze-drying process. The liposomal formulations provide therapeutically effective amounts of the photosensitizer for intravenous administration. In particular derivatives of chlorins and bacteriochlorins, such as temoporfin, are, hydrophobic photosensitizers whose efficacy and safety are enhanced by such liposomal formulations. The formulation can be efficiently freeze-dried preserving the size of the liposomal vehicles, and the content of a therapeutically effective amount of the photosensitizer, due to the selection of phospholipids and monosaccharides. The invention also relates to liposome compositions formed upon reconstitution with an aqueous vehicle. The freeze-dried formulation upon reconstitution with a suitable aqueous vehicle forms liposomes that are... |
| Low energy of excitation pdt compounds for treatment of ocular disease | 20060084951 | 20060420 |
| A photodynamic therapy includes a particular combination of a photosensitizer and light source for a photodynamic therapy used to treat ocular diseases. The photosensitizer has a peak excitation level when exposed to light of a given wavelength where the wavelength of light is absorbed at a particular location of the eye to be treated. The light source has a wavelength within the excitation range of the photosensitizer and matched to the location of the diseased eye tissue. The light source also has an irradiance level and energy level that is effective for therapy but at levels below the maximum permissible exposure level.
... |
| Detection and therapy of vulnerable plaque with fluorescent and/or radiolabeled compositions | 20060073100 | 20060406 |
| The present invention relates to methods for selectively targeting Photodynamic Therapy (“PDT”) to inflammatory components of vulnerable plaques. As such, the present invention provides methods for the identification of vulnerable plaques, using fluorescent compositions, which include photosensitizer compoisitions, and/or radiolabeled compounds, as well as methods to treat vulnerable plaques by selectively targeting and/or eliminating the inflammatory components of vulnerable plaques.
... |
